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Acute ischemic stroke is a leading cause of death and disability worldwide. Unlike 25 
myocardial infarction there is no current blood test to diagnose acute ischemic stroke. 26 
MicroRNAs are very stable in the blood and have been suggested as potential diagnostic 27 
markers. This review aimed to systematically assess case-control studies investigating the 28 
association of circulating microRNAs with acute ischemic stroke. Medline, CINAHL, Cochrane 29 
Library, Web of Science Scopus, and PubMed were searched for studies that examined the 30 
association of circulating microRNAs in acute ischemic stroke patients. Studies meeting specific 31 
inclusion and exclusion criteria (such as blood sample were obtained within 24 hours of an acute 32 
ischemic stroke) were selected for data extraction. Two authors extracted data from the included 33 
studies relevant to study design, patient characteristics, and relative microRNA expression. Eight 34 
studies were included involving 572 cases and 431 healthy controls. Twenty-two microRNAs 35 
(12 up-regulated and 10 downregulated) were reported as differentially expressed. Only one 36 
microRNA, miR-106b, was reported as differentially expressed in at least 2 studies. Significant 37 
heterogeneity in the design and methods of the included studies was noted. Differential 38 
expression of a large number of microRNAs has been reported early following acute ischemic 39 
stroke. More research is required in larger patient populations to further evaluate the diagnostic 40 








 Stroke is the second leading cause of death and third leading cause of disability 48 
worldwide with an incidence of 16.9 million cases globally in 2010 [1]. The main causes of 49 
ischemic stroke are large artery athero-thrombosis and cardiac embolism [2].  The main 50 
treatments for ischemic stroke are mechanical and chemical thrombolysis [3, 4], however these 51 
treatments need to be administered rapidly following the stroke to be effective [5]. Thrombolysis 52 
is also associated with a risk of bleeding, including intracranial hemorrhage [6].  Rapid and 53 
accurate diagnosis of acute ischemic stroke is therefore critical to enable appropriate treatment. 54 
Currently diagnosis of acute ischemic stroke relies on neuroimaging techniques such as magnetic 55 
resonance imaging (MRI) and computed tomography (CT) scans, however the availability of 56 
such expensive machinery can be limited, and image interpretations may be inconsistent during 57 
the early stages of stroke [7]. Therefore, there is a need for a more rapid and simple tool for acute 58 
ischemic stroke diagnosis. Myocardial infarction is routinely diagnosed using blood markers and 59 
it has been suggested that circulating biomarkers could also be valuable for acute ischemic stroke 60 
diagnosis.  MicroRNAs (miRNAs) are small RNA molecules that may serve as valuable 61 
biomarkers due to their easy detection and stability in blood samples [8]. While many studies 62 
have investigated miRNA expression in acute ischemic stroke patients, there has been no 63 
previous systematic review of the diagnostic potential of miRNAs for acute ischemic stroke. This 64 
systematic review aimed to summarize previous research examining the association between 65 
circulating miRNAs and acute ischemic stroke in blood samples collected within 24 hours of 66 
stroke symptom onset. We focused on these studies as a circulating marker is needed in clinical 67 
practice for diagnosing acute ischemic stroke in presenting patients. 68 
 69 
 4 
Materials and Methods 70 
 This systematic review was performed in line with the reporting guidelines of the 71 
systematic review and meta-analysis (PRISMA) statement [9]. A protocol was developed 72 
following the guidelines of the PRISMA-P statement [10] and was published in the PROSPERO 73 
database (CRD42016036218). 74 
 75 
Search Strategy 76 
 A systematic literature search was conducted using Medline (via Ovid MEDLINE®, 77 
1946 to February Week 4 of 2016), CINAHL, Cochrane Library, Web of Science (1965 to 78 
2016), Scopus (1960-2016), and PubMed. Searches were performed with a combination of 79 
MeSH (medical subject headings) terms and keyword terms. Medline, CINAHL, and Cochrane 80 
Library were searched with MeSH terms “MicroRNAs” AND “Biomarkers OR Genetic 81 
Markers” AND “Stroke”. With aid from a librarian with specified skills for database searching, 82 
the following search string was developed and used in all of the chosen databases: "micro rna" 83 
OR microrna* OR mirna* OR "small temporal rna" OR strna AND "biochemical marker" OR 84 
"biochemical markers" OR "biologic marker" OR "biologic markers" OR "biological marker" 85 
OR "biological markers" OR biomarker* OR "clinical marker" OR "clinical markers" OR 86 
"immune marker" OR "immune markers" OR "immunologic marker" OR "immunologic 87 
markers" OR "laboratory marker" OR "laboratory markers" OR "serum marker" OR "serum 88 
markers" OR "surrogate end point" OR "surrogate end points" OR "surrogate endpoint" OR 89 
"surrogate endpoints" OR "surrogate marker" OR "surrogate markers" OR "viral marker" OR 90 
"viral markers" AND "cerebrovascular accident" OR "cerebrovascular accidents" OR stroke* OR 91 
apoplex* OR "brain vascular accident" OR "brain vascular accidents" OR cva* OR "cerebral 92 
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vascular accident" OR "cerebral vascular accidents" OR "brain infarction"  OR "brain 93 
infarctions" OR "brain venous infarction" OR "brain venous infarctions".  94 
 95 
Study Selection 96 
 The studies included in this review were selected based on the following inclusion and 97 
exclusion criteria. 98 
Studies were included if: 99 
1. They had a case-control design; 100 
2. The cases included acute ischemic stroke patients who were evaluated by neuroimaging; 101 
3. The controls were healthy participants; 102 
4. Blood samples were collected within 24 hours of stroke symptom onset, enabling 103 
identification of miRNAs which rapidly change immediately after stroke; 104 
5. They evaluated the expression level of circulating miRNAs in blood samples from both 105 
cases and controls.  106 
Studies were excluded if: 107 
1. They investigated miRNA levels solely in animal models;  108 
2. They had a total case population of less than 50 persons; 109 
3. The article was not available in English. 110 
Studies were still included if a subset of the included participants met the inclusion 111 
criteria, as long as miRNA data could be extracted for the subset of individuals that satisfied the 112 
inclusion criteria. The titles and abstracts of articles obtained from the search strategy were 113 
scanned to identify unique eligible studies. Eligible studies were selected for inclusion after a full 114 
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text analysis. A further search was performed within the reference lists of studies and reviews 115 
obtained from the database search.  116 
 117 
Data Extraction 118 
 Two people (BD and DM) independently performed data extraction using a pre-119 
determined data extraction form (S1 Table). This form was designed to collect information 120 
regarding general patient characteristics, including stroke associated risk factors, case and 121 
control definitions, methods of miRNA quantification, and expression levels of circulating 122 
miRNAs. If data were not provided in the article or supplementary information, the 123 
corresponding author was contacted to request the missing information. miRNA data that was 124 
not numerically stated and not supplied after contacting authors was extrapolated from published 125 
figures using Adobe Photoshop CC (2015). A consensus meeting was held between the two 126 
reviewers to resolve any differences.  127 
 128 
Quality Assessment 129 
 The quality of the included studies were assessed using a modified QUADAS 2 tool (S2 130 
Table) [11]. This tool was modified to include questions specific to miRNA research and acute 131 
ischemic stroke.  Questions evaluated the reported definitions and diagnoses of stroke, the 132 
methods of miRNA evaluation, and the reporting of confounding risk factors. The questions 133 
were answered with ‘Yes’, ‘No’, or ‘Unclear’ and scored as per the evidence based librarianship 134 
critical appraisal tool [12]. Two authors (BD and DM) independently and blindly scored the 135 
studies as the total number of ‘Yes’ responses. Any discrepancies of 2 or more points were 136 
discussed in a consensus meeting and conflicts were resolved. Studies were deemed as high 137 
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quality, moderate quality, or low quality if the average quality assessment scores were ≥75%, 50-138 
75%, or ≤50%, respectively. 139 
 140 
Results 141 
Literature Search  142 
 The initial search of the databases yielded 339 papers eligible for inclusion. After 187 143 
duplicates were removed, 152 unique abstracts were screened for eligibility. Of these, 132 were 144 
excluded due to not meeting the inclusion criteria, or they were review papers. The full texts of 145 
the remaining 20 studies were assessed. Twelve of these studies were excluded, mainly due to 146 
blood samples not being obtained within 24 hours of stroke onset, thereby prohibiting assessment 147 
of changes in miRNA expression related to stroke onset and/or assessment of patient populations 148 
<50 persons. A total of 8 studies satisfied the inclusion and exclusion criteria and were included 149 
in this review (Figure 1) [13-20]. 150 
 151 
Fig 1. Outline of the literature search and study selection process. No additional studies were 152 
added after searching through reference lists of publications identified during the search 153 
 154 
Quality Assessment 155 
 The quality assessment suggested that two studies were of high quality [15, 18], four 156 
studies of moderate quality [16, 17, 19, 20], and two studies of low quality [13, 14] (S2 Table). 157 
Only two of the studies adjusted for confounding risk factors of stroke, one of which received the 158 
highest quality score [15] and the other receiving the lowest quality score [14]. The two studies 159 
with high quality scores successfully defined their controls as having no prior history of stroke, 160 
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reported on stroke risk factors for patients, and avoided pooling blood samples for miRNA 161 
detection [15, 18]. In contrast, the two studies with low quality scores did not meet these criteria 162 
and failed to report p-values for the miRNAs that were reported to be differentially expressed 163 
[13, 14]. The study receiving the lowest quality score was the only study in which controls were 164 
not age and sex matched to the acute ischemic stroke cases[14]. 165 
 166 
Study Design and Methods 167 
 The design and methods of the included studies are summarized in Table 1. Seven of the 168 
studies were performed in China [13, 15-19] and one in Singapore [14].  Three studies diagnosed 169 
acute ischemic stroke based on clinical signs of neurological deficit [15-17] and four diagnosed 170 
acute ischemic stroke based on cerebral infarction using MRI and/or CT [13, 14, 19]. One study 171 
stated patients were assessed for neurological deficit and examined by MRI with diffusion 172 
weighted imaging (DWI), however, it was unclear which method was used for diagnosis of acute 173 
ischemic stroke [18]. The definitions of controls varied between the studies as either having no 174 
physical evidence of stroke [13, 15], no prior history of stroke [15, 18], or having no stroke 175 
associated risk factors [19]. Four of the studies had control groups that were not clearly defined 176 
[14, 16, 17, 20]. The majority of the studies assessed the plasma [13, 15, 16, 20] and serum [17-177 
19] from the blood samples, and one study assessed whole blood samples [14]. In three studies 178 
primary screening of blood samples was performed with a microarray chip followed by 179 
verification of microarray data using quantitative reverse transcription-Polymerase Chain 180 
Reaction (qRT-PCR) [13, 14, 17]. The remaining studies investigated specific miRNAs based on 181 
previous research [15, 16, 19]. All studies quantified differentially expressed miRNAs directly 182 
from blood samples by qRT-PCR using various housekeeping genes [13-20] 183 
 9 
Table 1. Study design and methodology of the included studies. 184 
 185 
Reference  Country Definition of stroke Definition of control Sample type  Primary screening/validation † miRNA quantification 
[13] China Radiographic diagnosis No evidence of stroke Plasma 
•Agilent miRNA microarray (1347 
miRNAs) 
•pooled samples (n=76 AIS) 
•miRNAs validated with qRT-PCR 
assay (n=76 AIS) 
•RT and qPCR 
•RNU6B control 
•relative expression via  2-ΔΔCt 
 
[14] Singapore Radiographic diagnosis Unclear Whole blood 
•miRCURY LNA array 
•individual and pooled samples (n=68 
AIS) 
•10 random miRNAs validated with 
qPCR (n=169 AIS) 
•RT and qPCR 
•RNU44 control 




Clinical diagnosis and 
radiographic diagnosis 
No evidence of stroke 
and no prior history of 
cerebrovascular disease 
Plasma N/A 
•RT and qPCR 
•U6 control 
•relative expression via  2-ΔΔCt 
[16] China 
Clinical diagnosis and 
radiographic diagnosis 
Unclear Plasma N/A 
•RT and qPCR 
•synthetic RNA oligonucleotide 
from each miRNA sequence 
•miRNA copy numbers calculated 
via standard curve 
[17] China 
Clinical diagnosis and 
radiographic diagnosis 
Unclear Serum 
•miRCURY LNA Array (3100 
miRNAs) 
•pooled samples (n=40 AIS) 
•miRNAs validated with qRT-PCR 
(n= 22 AIS) 
•RT and qPCR 
•syn-cel-lin-39 control 
•relative expression via  2-ΔΔCt 
 
[18] China Unclear 
No prior history of 
cerebrovascular disease 
Serum 
•primary screening of 9 miRNAs by 
qRT-PCR (n=30 AIS) 
•RT and qPCR 
•U6 control 
•relative expression via  2-ΔΔCt 
[19] China Radiographic diagnosis 
No cerebrovascular risk 
factors 
Serum N/A 
• RT and qPCR 
•18S rRNA control 
•relative expression via  2-ΔΔCt 
[20] China 
Clinical diagnosis and 
radiographic diagnosis 
Unclear Plasma N/A 
• RT and qPCR 
•cel-mir-39 
•relative expression via  2 exp 
(mean Ct spiked-in controls - Ct 
target miRNA) and log transformed 
 10 
AIS, acute ischemic stroke; RT, reverse transcription; qPCR, quantitative polymerase chain reaction. N/A, not applicable 186 
† Primary screening methods and validation of primary screening may have included a separate patient population not specific to 187 
those analyzed within 24 hours; n number of patients used in each phase is state 188 
 189 
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Patient Characteristics 190 
 A summary of the characteristics of the cases and controls included in the 8 studies are 191 
presented in Table 2. In studies where only a sub-set of patients met the inclusion criteria the 192 
characteristics of these patients are reported unless otherwise stated. The acute ischemic stroke 193 
case number ranged from 38 to 146 [15, 18], with the mean age of patients ranging from 50 to 72 194 
[13, 19]. In all of the studies at least 50% of the cases were male (range 50% to 72.4%). Six out 195 
of the eight studies reported stroke associated risk factors with a large percentage of the cases 196 
having hypertension [14-16, 18, 19]. The risk factors in controls varied from having no risk 197 
factors [14, 19, 20], to greatly reduced prevalence of risk factors compared to cases [15], or 198 
similar prevalence to the cases [18].  Three studies did not report the risk factors for controls [13, 199 
16, 17]. An attempt was made to contact the corresponding authors to obtain missing data 200 










Table 2. Characteristics of acute ischemic stroke patients and healthy controls included in this systematic review. 210 
Reference 
AIS Cases Healthy Control 
n* Age M% HT% DM% HL% S% n* Age M% HT% DM% HL% S% 
[13] 76 50 ± 13 † 55.1 ns ns ns ns 116 53 ± 11 51.7 ns ns ns ns 
[14] 45 59.7 ± 1.39 † 61.4† 77.6† 44.6† 75.3† ns 24 39.0 ± 8.10 75 0 0 0 ns 
[15] 38 62.4 ± 5.9 ‡ 50 18.4 13.1 15.8 18.4 50 64 ± 6 48 10 10 12 20 
[16] 74 72 [18] 43-92 †§ 50.5† 74.2† 34.4† 18.3† 15.1† 23 65 § 69.6 ns ns ns ns 
[17] 53 68 ± 10.9 58.5 ns ns ns ns 50 67 ± 8.5 58.0 ns ns ns ns 
[18] 146 67.29 ± 14.16 76.7 86.3 39.1 74.6 44.5 96 63.23 ± 15.24 66.7 72.9 34.3 35.4 43.7 
[19] 72 72.4 ± 9.2 56.9 31.9 23.6 26.4 22.2 51 70.7 ± 7.5 58.8 0 0 0 17.6 
[20] 68 64 (55-76) § 66.2 54.4 25.0 11.7 26.5 21 58 (54-67) § 52.6 0 0 0 0 
 211 
AIS, acute ischemic stroke; n, number of acute ischemic stroke patients or healthy controls; M%, male percentage of the population; 212 
HT%, percentage of population with hypertension; DM%, percentage of population with Diabetes Mellitus; HL%, percentage of 213 
population with hyperlipidemia; S%, percentage of current smokers; ns, data not stated; N/A, applicable. Age is stated in years (mean 214 
± SD) unless otherwise specified. 215 
* n number of acute stroke patients in the study who had blood sample collection within 24 hours and who were involved in the 216 
analysis producing the extractable miRNA data (Table 3), or the number of controls involved in the analysis.  217 
† Representative of a larger patient population used in the study and is not specific to reported ‘n’ population  218 
‡ Data calculated as pooled mean and standard deviation from ages of subgroups  219 
§ Data expressed as medians [interquartile range] range. 220 
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Circulating miRNAs and their relative expression 221 
 The extracted miRNA data includes differentially expressed miRNAs quantified directly 222 
from blood samples that were collected within 24 hours of stroke. This excluded data from 223 
primary screening to avoid pooled samples. The miRNAs identified as differentially expressed in 224 
the blood of acute ischemic stroke patients varied greatly amongst the studies and are 225 
summarized in Table 3. A total of 22 miRNAs were reported as differentially expressed across 226 
all studies with 12 reported to be upregulated and 10 reported to be downregulated in stroke 227 
cases relative to healthy controls. Six of the 22 miRNAs (let-7b, miR-16, miR-21, miR-106b, 228 
miR-320d and miR-1246) were identified during primary screening in other included studies [13, 229 
14] however were not selected for further quantification in these studies for reasons that were not 230 
always made clear and thus were not reported in this review. miR-106b was the only miRNA 231 
reported to be differentially expressed in a common direction in more than one study [13, 17]. 232 
Two studies reported significant up-regulation of miR-106b in the blood of acute ischemic stroke 233 
patients compared to healthy controls, although the relative expression of this miRNA varied 234 
greatly (1.46-fold up-regulation [17] versus 23.9-fold up-regulation [13]). Two members of the 235 
let-7 family were reported to be associated with acute ischemic stroke. In one study let-7b was 236 
reported as downregulated (0.208-fold) in patients with large artery atherosclerosis stroke but 237 
upregulated (9.45-fold) in patients with cardioembolic stroke [15]. In another study let-7e was 238 
reported to be 1.77-fold upregulated in acute ischemic stroke patients compared to healthy 239 
controls [19]. Two members of the miR-320 family (miR-320d and miR-320e) were reported as 240 
downregulated in acute ischemic stroke patients (Table 3) [13]. The other 17 miRNAs reported 241 
as differentially expressed in acute ischemic stroke patients were identified in single studies and 242 
varied in expression relative to healthy controls (Table 3).243 
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Table 3. miRNAs reported to be significantly differentially expressed in blood samples obtained within 24 hours of onset of acute 244 
ischemic stroke. 245 
 246 
miRNA Relative expression* Up/down regulated p-value 
ROC analysis:  
AUC (95%CI); p-value; n 
let-7b 0.209; 9.36 [15] † Downregulated; upregulated†  <0.05; <0.05 0.93 (0.879-0.980); p-value ns; n=38 
let-7e 1.77 [19]  Upregulated 0.0091 0.86 (0.754-0.968); p-value ns; n=72 
miR-16 1.33 [16] Upregulated 0.0088 N/A 
miR-21 0.252 [20] Downregulated <0.05 N/A 
miR-23a 0.43 [18]  Downregulated <0.01 N/A 
miR-24 0.287 [20] Downregulated <0.05 N/A 
miR-27a 7.28 [14] Upregulated ns 0.88 (0.81-0.96); p-value ns; n=101 ‡ 
miR-30a 0.288; 0.266 [15] † Downregulated; downregulated† <0.05; <0.05 0.91 (0.869-0.979); p-value ns; n=38 
miR-32-3p 1.58 [17] Upregulated <0.05 N/A 
miR-106b-5p 
23.90 [13]  





0.962 (0.930-0.993); p =0.000; n=76 
N/A 
miR-125b-2 2.75 [14] Upregulated ns 0.85 (0.77-0.93); p-value ns; n=101‡ 
miR-126 0.0505; 0.0505 [15] † Downregulated; downregulated† <0.05; <0.05 0.92 (0.871-0.978); p-value ns; n=38 
miR-145 7.72 [18]  Upregulated <0.001 N/A 
miR-221 0.154 [18]  Downregulated <0.001 N/A 
miR-320d 0.07 [13] Downregulated ns 0.987 (0.972-1.000); p=0.000; n=76 
miR-320e 0.13 [13] Downregulated ns 0.981 (0.963-0.998); p=0.000; n=76 
miR-422a 2.63 [14] Upregulated ns 0.86 (0.75-0.97); p-value ns; n=101 ‡ 
miR-488 2.77 [14] Upregulated ns 0.86 (0.72-0.92); p-value ns; n=101 ‡ 
miR-532-5p 0.696 [17] Downregulated <0.01 N/A 
miR-627 5.50 [14] Upregulated ns 0.76 (0.66-0.87); p-value ns; n=101‡ 
miR-1246 1.95 [17] Upregulated <0.05 N/A 
miR-4306 5.30 [13] Upregulated ns 0.952 (0.922-0.982); p =0.000; n=76 
 247 
ROC, receiver operator characteristic; AUC, area under the curve; ns, not stated; N/A, not applicable. p-values are reported from the 248 
included studies for miRNA expression differences in cases versus controls. 249 
*Relative expression given as a ratio to healthy control group. Relative ratios were either obtained directly from the article or were 250 
calculated using miRNA expression levels from cases and controls to generate a ratio.   251 
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† The relative expression in patients from TOAST classification subgroups with large vessel atherosclerosis (n=10) and 252 
cardioembolism (n=9), respectively. miRNA levels were also reported in the study for other subgroups [15].   253 
‡ ROC analysis included a larger patient population not specific to those analyzed within 24 hours; n number of patients used in the 254 





Assessment of the diagnostic potential of circulating microRNAs for 259 
acute ischemic stroke 260 
Four of the studies performed receiver operator characteristic (ROC) analyses to examine 261 
the diagnostic potential of the differentially expressed miRNAs [13-15, 19]. The highest area 262 
under the curve (AUC) value was reported for miR-320d (0.987) [13] while the lowest AUC 263 
value (0.76) was reported for miR-627 (Table 3) [14]. Only one of the two studies that associated 264 
miR-106b with acute ischemic stroke performed a ROC analysis and reported an AUC of 0.962 265 
[13]. Let-7b, miR-126, miR-30a, miR-320e, and miR-4306 were each reported to have AUC 266 
values greater than 0.90 [13, 15].  267 
 268 
Discussion 269 
 Following a systematic literature search, we identified 22 circulating miRNAs reported to 270 
have an association with acute ischemic stroke. Of these, only miR-106b was consistently 271 
reported as significantly upregulated in more than one study, however the relative expression 272 
varied substantially between the 2 studies [13, 17]. These findings contradicted those of another 273 
included study that reported down-regulation of miR-106b in acute ischemic stroke patients [14]. 274 
Sepramaniam and colleagues reported down-regulation of miR-106b and let-7b in both acute 275 
ischemic stroke and stroke recovery patients, thus were not selected for further assessment in 276 
their study due to not being unique to acute ischemic stroke [14].  Similarily, the down-277 
regulation of miR-21 reported in this review was contradicted by that of another included study, 278 
which demonstrated differential up-regulation of miR-21 during primary screening [13]. Wang 279 
and colleagues did not select miR-21 for further assessment in their study [13] for reasons that 280 
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remain unclear. Other included studies demonstrated miR-16, miR-320d and miR-1246 to be 281 
differentially expressed in acute ischemic stroke patients in a similar direction to findings 282 
observed in this review, however, they were not selected for further assessment in these studies 283 
for reasons that were not clear [13, 14].  284 
Multiple factors may have contributed to the observed differences in miRNA expression 285 
between the studies. Firstly, the participant characteristics varied between the studies. The 286 
controls varied from those with similar risk factors to the cases to those with no risk factors [14, 287 
15, 19, 20]. Two of the studies did not report stroke risk factors for the ischemic stroke patients 288 
[13, 17]; therefore it is unclear how these unknown variables may have affected the reported 289 
results. Secondly, the sample sizes of stroke patients and controls also varied substantially both 290 
between the studies and between each miRNA identification phase (primary screening, 291 
validation, and miRNA quantification). Thirdly, the methods of miRNA assessment varied 292 
between the studies. The type of blood medium analyzed varied across the studies and likely 293 
effected the relative concentrations of reported miRNAs [13-20]. Additionally, three of the 294 
studies employed microarray chips for primary identification of miRNAs with varying rationale 295 
for selection of miRNAs for further assessment [13, 14, 17], while other studies assessed 296 
miRNAs based on past research [15, 16, 18-20]. Across all the studies a number of different 297 
housekeeping genes were used during miRNA quantification, which may have effected the 298 
normalization of miRNA expression. Finally, different classifications of stroke within the 299 
included patients may have contributed to the variations in miRNA expression. Large artery-300 
atherosclerotic stroke and cardioembolic stroke occur by different pathological mechanisms and 301 
this may affect the relative expression of some miRNAs. This is supported with data from one 302 
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included study that reported a substantial difference in let-7b expression for large artery-303 
atherosclerotic stroke and cardioembolic stroke [15].  304 
The diagnostic potential of the reported miRNAs is difficult to assess since only 4 of the 305 
included studies performed ROC analysis with varying outcomes. Of the 13 miRNAs reported 306 
with AUC values let-7b, miR-30a, miR-106b, miR-126, miR-320d, miR-320e, and miR-4306 307 
were reported to have AUC values greater than 0.90. A previous study identified differential 308 
expression of these miRNAs in brain and blood samples of a rat ischemic stroke model [21]. 309 
However, of these only miR-320 was identified as both differentially expressed in brain and 310 
blood samples of the rat model [21], suggesting they were representative of the acute brain 311 
response to stroke. This is consistent with findings from this review where miR-320d and miR-312 
320e were reported to have the highest AUC values amongst the 20 miRNAs. More research is 313 
required on the miRNAs identified in this review to further assess their potential as biomarkers 314 
for acute ischemic stroke.  315 
The current review has a number of limitations. Firstly only 8 studies met our inclusion 316 
criteria and only 2 were considered to be of high quality. This suggests that the potential for 317 
miRNAs to diagnose stroke remains poorly investigated, and there is a need for additional high-318 
quality studies to more thoroughly assess their clinical usefulness. Secondly, there is substantial 319 
heterogeneity in the reported results from the included studies. The large variation in the reported 320 
miRNAs makes the applicability of these findings for future diagnostics difficult to determine. 321 
Thirdly, due to only including patients with blood samples collected within 24 hours, several 322 
studies were excluded. We used this approach to focus on diagnostic markers that could be used 323 
early after stroke, which is the current clinical requirement. Finally, the designs of the included 324 
studies had inherent limitations.  For example, all of the studies included Asian populations so it 325 
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is unclear whether these results are representative of other ethnic groups. The sample sizes of the 326 
included studies were relatively small. Additionally, most of the studies did not adjust for 327 
confounding risk factors. Therefore, interpretation of the results presented in this review should 328 
be made cautiously.  329 
 330 
Conclusion 331 
 In conclusion this systematic review reports a large number of circulating miRNAs to be 332 
differentially expressed in acute ischemic stroke patients in blood samples collected within 24 333 
hours of symptom onset. Currently miR-106b is the only miRNA to have been reported as 334 
differentially expressed in patients within 24 hours of ischemic stroke in more than one study. 335 
The highest AUC were reported for miR-320d and miR-320e and therefore these may have the 336 
best diagnostic potential although this remains to be confirmed in larger studies. Further studies 337 
employing larger and more diverse populations with better adjustment for confounding risk 338 
factors are required to determine the clinical value of miRNAs as biomarkers for acute ischemic 339 
stroke.  340 
 341 
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